Selective i-wave attenuation in unilateral high myopia
摘要
Bipolar cell activity plays a crucial role in myopia development. The light-adapted electroretinogram has its photoreceptoral (a-wave) and post-receptoral (mainly b-wave) origins with a later i-wave component primarily representing the activation of the OFF-bipolar cells. It has been proposed that retinal OFF-pathway alteration may contribute to the development of myopia. Therefore, elucidating specific electroretinography (ERG) changes in individuals with unilateral high myopia (UHM) could contribute to understand the underlying pathomechanisms of myopia development and devise targeted treatment options.
PurposeThis study aimed to compare light-adapted ERG waveforms between low-myopic/emmetropic and highly myopic eyes in patients with UHM eyes sharing an identical genetic blueprint. The subsequent comparison of the responses between highly myopic and healthy fellow eyes aimed to investigate possible photoreceptoral and/or post-receptoral pathway alterations that may play a role in myopic refractive errors.
MethodsOphthalmological and electrophysiological examinations were carried out in four individuals with UHM [mean interocular difference in spherical equivalent : 10.12 ± 2.7 (7 -13.5) D]. ISCEV standard light-adapted electroretinograms were recorded from both eyes using LKC RETeval® portable ERG unit and DTL electrodes under pupil dilation.
ResultsThe results showed comparable a- and b-wave amplitudes with consistently reduced i-wave amplitudes in the highly myopic eyes compared to the lower- or non-myopic fellow eyes.
ConclusionThese findings suggest that, beyond genetic susceptibility and in the absence of overt unilateral ocular pathology, additional modulatory influences may contribute to the localized retinal regulatory mechanisms. Moreover, the i-wave appears to be a promising electrophysiological biomarker capable of detecting subtle alterations in retinal signaling, with potential implications for elucidating myopia pathogenesis and guiding targeted therapeutic development.